SC10: Microfluidics and Other Devices for POCT

SUNDAY, MARCH 1 | 5:30 - 8:30 PM (DINNER PROVIDED)

ABOUT THIS COURSE:

This short course will provide an overview of microfluidic techniques, including valved and valve-less devices, pumped systems, and capillary flow approaches. Practical examples will keep the discussion grounded in the realization of commercializable devices. We will discuss engineering approaches to enhance the advantages and minimize the challenges. Throughout, the science will be linked to the commercial case for these devices, including a full discussion of a recent success story of a centrifugal microfluidic molecular assay system.

TOPICS TO BE COVERED:

  • Technology overview
  • Commercialization issues

COURSE AGENDA:

5:30 pm Course Introduction and Presentations Begin

6:15 Dinner Buffet

6:45 Course Resumes

8:30 Course Ends

WHO SHOULD ATTEND:

Anyone interested in learning more about the point-of-care technology trends and challenges.

INSTRUCTORS:

Buchanan-KrisKris Buchanan, CEO, Phase Three Product Development

Kris Buchanan is the CEO and founder of Phase Three Product Development. He is a biomedical and systems engineer who has worked in all phases of product development for over 30 years. Kris is also the inventor or co-inventor of more than 75 USPTO and international patents. Kris has a history of building and leading product development teams and even R&D divisions of large companies and had an extensive network of engineers, assay developers, and other technical specialists. At Phase Three, he has assembled an all-star team of experienced engineers and scientists with pre-built communication systems and an understanding of competencies.

Evan F Cromwell, President & CEO, Protein Fluidics

Evan is the founder, President and CEO of Protein Fluidics, Inc. Protein Fluidics provides protein analysis and immunoassay systems using microfluidics to accelerate data driven decisions in the laboratory. He has over 30 years of senior executive and technical expertise in numerous hi-tech industries including hard disk drive, semiconductor, telecom, and biotechnology. He has been involved in all phases of the design, development, and manufacture of systems for biological assays, materials analysis, optical inspection, and process control. Prior to Protein Fluidic, Evan served as the President and CEO of Blueshift Biotechnologies, a high-content screening and analysis venture that was acquired by Molecular Devices, a Danaher company, in 2008. At Molecular Devices, Evan led global technology development initiatives for novel Life Sciences products, directed an assay development group, and chaired the company’s scientific advisory board. Evan’s passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities. Evan holds a B.S. in Chemistry from Caltech and earned his Ph.D. in Physical Chemistry at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 16 patents

Myatt-ChrisChris Myatt, Founder & CEO, MBio Diagnostics, Inc.

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a BS in Physics and a BA in Mathematics at Southern Methodist University. Chris also earned a PhD in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Richard Spero, PhD, Co-founder, CEO, Redbud Labs

Richard Spero is co-founder and CEO of Redbud Labs, and co-inventor of Redbud’s biomimetic cilia technology. Trained as a physicist and systems engineer, Dr. Spero has contributed to the discovery of novel methods for fluid processing at the microscale, including pumping, mixing, cell sorting, and analyte isolation. Prior to founding Redbud Labs, Dr. Spero earned his PhD in Physics at the University of North Carolina at Chapel Hill, where he studied blood clot rheology and developed novel systems for magnetic manipulation and time-dependent high content screening. 

Back to Short Courses


Premier Sponsors

NeoGenomics

Seegene